4-(2-(4-chlorophenyl)-1-((4-chlorophenyl)amino)ethyl)benzene-1, 3-diol is a potential agent for gout therapy as a dual inhibitor of XOD and NLRP3

Phytomedicine. 2018 Mar 15:42:9-17. doi: 10.1016/j.phymed.2018.03.007. Epub 2018 Mar 6.

Abstract

Backgound: Gout is an inflammatory arthritis characterized by abrupt self-limiting attacks of inflammation caused by precipitation of monosodium urate crystals (MSU) in the joint. Both anti-hyperuricemia and anti-inflammation could be gout therapeutic strategies, whereas ideal drugs for gout treatment are deficient.

Purpose: 4-(2-(4-chlorophenyl)-1-((4-chlorophenyl)amino)ethyl)benzene-1, 3-diol (CBED) was obtained from a cluster of deoxybenzoins derivatives synthesized by our research group with potent anti-hyperuricemic and anti-inflammatory activities, which was expected to be a dual inhibitor of xanthine oxidase (XOD) and NOD-like receptor protein 3 (NLRP3). This study aimed to investigate effects of CBED on XOD and NLRP3 in vitro, as well as the possible mechanisms by which CBED improved gout in vivo.

Methods: After molecular docking detection, inhibitory effects of CBED on XOD and NLRP3 were evaluated in vitro. Subsequently, hyperuricemia and acute gouty arthritis animal models were established by potassium oxonate or MSU, respectively. After CBED treatment, serum uric acid levels, synovial interleukin (IL)-1β concentrations, hepatic XOD activities, as well as synovial morphological changes were examined. More importantly, synovial expressions of NLRP3 inflammasome components including NLRP3, apoptosis-associated speck-like protein (ASC) and caspase-1 in rats were analyzed by immunofluorescence and western blot.

Results: In vitro, CBED obviously inhibited XOD activity with an IC50 value of 3.87 µM, moreover, it effectively inhibited MSU-induced NLRP3 inflammasome activation and IL-1β over-production in THP-1 cells. In addition, CBED dose-dependently decreased serum uric acid levels suppressed hepatic XOD activities in oxonate-induced hyperuricemic mice. On the other hand, CBED significantly improved MSU-induced ankle swelling and histopathological damage with elevated IL-1β. In addition, NLRP3 inflammasome activation could be blocked by CBED treatment in rats with acute gouty arthritis. Notbly, CBED exhibited no effects on all these indicators in normal animals, predicting its safety.

Conclusions: CBED might serve as a dual XOD and NLRP3 inhibitor for treatment of gout.

Keywords: 4-(2-(4-chlorophenyl)-1-((4-chlorophenyl)amino)ethyl)benzene-1, 3-diol; Dual inhibitor; Gout; NLRP3; XOD.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Benzene Derivatives / pharmacology*
  • Benzene Derivatives / therapeutic use
  • Enzyme Inhibitors / pharmacology*
  • Enzyme Inhibitors / therapeutic use
  • Gout / drug therapy*
  • Humans
  • Hyperuricemia / drug therapy*
  • Inflammasomes / metabolism
  • Liver / drug effects
  • Liver / enzymology
  • Male
  • Mice
  • Mice, Inbred NOD
  • Molecular Docking Simulation
  • NLR Family, Pyrin Domain-Containing 3 Protein / antagonists & inhibitors*
  • NLR Family, Pyrin Domain-Containing 3 Protein / chemistry
  • NLR Family, Pyrin Domain-Containing 3 Protein / metabolism
  • Rats, Sprague-Dawley
  • Uric Acid / blood
  • Xanthine Oxidase / antagonists & inhibitors*
  • Xanthine Oxidase / chemistry
  • Xanthine Oxidase / metabolism

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Benzene Derivatives
  • Enzyme Inhibitors
  • Inflammasomes
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Uric Acid
  • Xanthine Oxidase